Document is current
Any future updates will be listed below
-
Authors
Bermejo-Álvarez, Ismael https://orcid.org/0000-0003-2563-7908
Vázquez, Cristina https://orcid.org/0000-0002-1551-7913
Irigaray-Moreno, Alberto https://orcid.org/0009-0003-9498-8020
Quevedo-Romero, Ignacio https://orcid.org/0000-0003-0299-1146
Mediero, Aránzazu https://orcid.org/0000-0002-5368-574X
Herrero-Beaumont, Gabriel https://orcid.org/0000-0002-3241-991X
Largo, Raquel https://orcid.org/0000-0001-6525-2944
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PIE15/00048, PI18/00261 and PI22/00352)
Comunidad de Madrid (PEJ-2023-AI/SAL-GL-27952)
European League Against Rheumatism (Q223RSV96)
- License Information
-
More Information
Article History
Received: 30 April 2025
Accepted: 16 December 2025
First Online: 25 December 2025
Declarations
:
: All methods were performed in accordance with the relevant guidelines and regulations. This study involves the use of MSCs obtained from the adipose tissue from human healthy donor lipoaspirates after informed consent according to the approval by the Ethics Committee of Hospital Fundación Jiménez Díaz (Project “mRNA engineered mesenchymal stromal cells: a new generation of cell therapy for inflammation”, approved on October 19, 2017, PIC09/2016_Am). All animal experiments were performed by procedures approved by the Institutional Ethics and Animal Welfare Committee of IIS-FJD (Project “Mesenchymal stromal cells as inducers of inflammation resolution-specific mediators in the treatment of gouty arthritis. PROEX 139.7/20, approved on June 19, 2020).
: Not applicable.
: RL, IB-A and GH-B have filed a patent application (#23382935.7) on the use of SPMs mixtures for the treatment of diseases or conditions that involve acute inflammation. The authors declare no others conflict of interest.
